, Volume 41, Issue 12, pp 1568–1571 | Cite as

Quantitative differences in the pharmacological effects of (+)- and (−)-cathinone

  • R. Gugelmann
  • M. von Allmen
  • R. Brenneisen
  • H. Porzig
Short Communications


The optically pure isomers of cathinone were prepared by separating synthetic cathinone racemate and used to study central and peripheral effects of these indirect sympathomimetics in rats and guinea pigs. The (−)-isomer was significantly more potent than the (+)-isomer in stimulating locomotor activity whereas no difference was observed with respect to their cardiac effects. In analogy to observations with (+)- and (−)-amphetamine such variable isomer discrimination may be due to different stereoselectivities of amine uptake mechanisms in the target tissues.

Key words

(+)-Cathinone (−)-cathinone cardiac stimulation locomotor activity 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kalix, P., Gen. Pharmac.15 (1984) 179.Google Scholar
  2. 2.
    Schorno, H.X., Pharmazie unserer Zeit11 (1982) 65.Google Scholar
  3. 3.
    Rosencrans, J.A., Campbell, O.L., Dewey, W.L. and Harris, L.S., NIDA Res. Monogr.27 (1979) 328.PubMedGoogle Scholar
  4. 4.
    Glennon, R., and Showalter, D., Res. Commun. Subst. Abuse2 (1981) 186.Google Scholar
  5. 5.
    Schorno, H.X., and Steinegger, E., United Nations Document MNAR/3/1978.Google Scholar
  6. 6.
    Schorno, H.X., Diss., Bern 1979.Google Scholar
  7. 7.
    Takamatsu, H., J. pharm. Soc. Japan76, (1956) 1219.Google Scholar
  8. 8.
    Kuschinsky, G., Lindmar, R., and Wollert, U., Kurs der allgemeinen Pharmakologie und Toxikologie. Wissenschaftliche Verlagsgesellschaft, Stuttgart 1974.Google Scholar
  9. 9.
    McIntosh, J.E.A., and McIntosh, R.P., Mathematical Modelling and Computers in Endocrinology. Springer-Verlag, Berlin, Heidelberg, New York 1980.Google Scholar
  10. 10.
    Zelger, J.L., Schorno, H.X., and Carlini, E.A., Bull. Narc.32 (1980) 67.Google Scholar
  11. 11.
    Valterio, C., and Kalix, P., Archs int. Pharmacodyn. Ther.255 (1982) 196.Google Scholar
  12. 12.
    Taylor, K.M., and Snyder, S.H., Science168 (1970) 1487.PubMedGoogle Scholar
  13. 13.
    Kalix, P., Progr. Neuro-Psychopharmac. Biol. Psychiat.5 (1982) 43.Google Scholar
  14. 14.
    Kalix, P., Br. J. Pharmac.68 (1980) 11.Google Scholar
  15. 15.
    Kohli, J.D., and Goldberg, L.I., J. Pharm. Pharmac.34 (1982) 338.Google Scholar
  16. 16.
    Kalix, P., Drug Alcohol Dep.11 (1983) 395.Google Scholar
  17. 17.
    Schorno, H.X., and Steinegger, E., Experientia35 (1979) 572.Google Scholar
  18. 18.
    Weiner, N., in: The Pharmacological Basis of Therapeutics, 6th edn, p. 160. Eds A.G. Gilman, L.S. Goodman and A. Gilman. MacMillan, New York 1980.Google Scholar
  19. 19.
    Trendelenburg, U., in: Catecholamines. Hdbk exp. Pharmac. vol. 33, p. 348. Eds H. Blaschko and E. Muscholl. Springer-Verlag, Berlin 1972.Google Scholar
  20. 20.
    Testa, B., and Jenner, P., in: Drug Metabolism. Chemical and Biochemical Aspects, p. 238. Marcel Dekker, New York 1976.Google Scholar

Copyright information

© Birkhäuser Verlag 1985

Authors and Affiliations

  • R. Gugelmann
    • 1
  • M. von Allmen
    • 1
  • R. Brenneisen
    • 1
  • H. Porzig
    • 1
  1. 1.Pharmakologisches InstitutUniversität BernBernSwitzerland

Personalised recommendations